Quantcast

Latest Hypercholesterolemia Stories

2014-10-01 20:24:10

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in...

2014-09-22 12:31:09

DUBLIN, Sept. 22, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "PCSK9 and Other Novel Hypercholesterolemia Drugs" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Researchers have concluded that...

2014-09-15 16:29:14

Patients starting on generic statins vs. branded statins had an eight percent lower rate of cardiovascular events and death WOONSOCKET, R.I., Sept. 15, 2014 /PRNewswire/ -- A new study by researchers at CVS Health (NYSE: CVS) and Brigham and Women's Hospital published today in the Annals of Internal Medicine, is the first to investigate whether starting on a generic versus a brand-name drug for the treatment of high cholesterol is associated with improved health outcomes. The...

2014-09-15 16:26:30

LONDON, Sept. 15, 2014 /PRNewswire/ -- INTRODUCTIONWorldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Researchers have concluded that reduction of plasma LDL cholesterol (LDLC) is the cornerstone of assessing heart risk. Irrespective of baseline cholesterol concentration, each mmol/L LDLC reduction...

2014-09-10 23:11:45

According to the Center for Disease Control and Prevention, approximately one in every six Americans has high cholesterol. New York Times and USA Today Best Selling author, Sanjay Jain, M.D. MBA explains how to identify signs of high cholesterol and reduce cholesterol levels without the use of expensive medications. Washington, DC (PRWEB) September 10, 2014 Recent statistics from the Center for Disease Control and Prevention show that 17% of Americans--one out of every six adults--have...

2014-09-08 23:02:12

http://www.heartbeatexperts.com/ -- This Flash Report is a top-line view into Heartbeat Experts’ perspectives on stakeholder management needs for the Hypercholesterolemia-Hyperlipidemia market. New York, US (PRWEB) September 08, 2014 This Flash Report is a top-line view into Heartbeat Experts’ perspectives on stakeholder management needs for the Hypercholesterolemia-Hyperlipidemia market. Download the flash report to speak with Heartbeat Experts on stakeholder strategies for any...

2014-09-02 08:29:42

Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase...

2014-08-28 08:28:39

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent...

2014-08-28 08:28:27

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to...

2014-08-20 23:03:06

The research organization offers tips on how to help lower cholesterol. San Antonio, TX (PRWEB) August 20, 2014 Texas Medical Research Associates is looking for candidates to participate in their new study. The study will help test the effectiveness of a new drug looking to help lower cholesterol. People who suffer from high cholesterol may be eligible to participate in the study. According to the American Heart Association, too much cholesterol in the blood can lead to cardiovascular...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related